A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

Exclusion Criteria

• •History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic or psychiatric disease or any other condition which, in the opinion of the Investigator would jeopardize the safety of the subject or the validity of the study results.
• •Has a clinically significant abnormal finding on the physical exam, medical history or clinical laboratory results at screening.
• •History or presence of allergic or adverse response to the study drug or related drugs.
• •Has been on a significantly abnormal diet during the four weeks preceding the first dose of study medication.
• •Has donated blood or plasma within 30 days prior to the first dose of study medication.
• •Has participated in another clinical trial within 30 days prior to first dose of study medication.
• •Has used any over-the-counter (OTC) medication including vitamins, within 7 days prior to the first dose of study medication.
• •Has used any prescription medication, except hormonal contraceptive or hormonal replacement therapy, within 7 days prior to the first dose of study medication.
• •Has been treated with any known enzyme altering drugs such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study medication.
• •Has smoked or used tobacco products within 60 days prior to the first dose of study medication.
• •Female with a positive pregnancy test.
• •Positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates).
• •Has had a positive test for, or has been treated for hepatitis B, hepatitis C or HIV.